ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer

Trial Profile

ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms ATTRACTION-2
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 06 Oct 2017 Results (data cut off: 13 Aug, 2016) assessing the efficacy and safety of nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens, published in the Lancet.
    • 22 Sep 2017 Results presented in a Bristol-Myers Squibb media release.
    • 22 Sep 2017 According to a company media release, ONO has received approval for OPDIVO (nivolumab) intravenous infusion for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy as a partial change in approved items of manufacturing and marketing approval in Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top